Track market-moving stories before they get noisy

-

BOSTON--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) (the “Company”), a trusted technology partner to medical and advanced technology equipment manufacturers, will release its first quarter 2026 results after the close of U.S. financial markets on Monday, May 11, 2026.

The Company will host a conference call on Tuesday, May 12, 2026, at 8:00 a.m. ET to discuss these results. To access the call, please dial (888) 346-3959 before the scheduled conference call time. Alternatively, the conference call can be accessed online via a live webcast on the Events & Presentations page of the Investors section of the Company’s website at www.novanta.com.

A replay of the audio webcast will be available approximately three hours after the conclusion of the call on the Events & Presentations page of the Investors section of the Company’s website at www.novanta.com. The replay will remain available until Monday, July 06, 2026.

About Novanta

Novanta is a leading global supplier of core technology solutions that give medical, life science, and advanced industrial original equipment manufacturers a competitive advantage. We combine deep proprietary expertise and competencies in precision medicine, precision manufacturing, robotics and automation, and advanced surgery with a proven ability to solve complex technical challenges. This enables Novanta to engineer proprietary technology solutions that deliver extreme precision and performance, tailored to our customers' demanding applications. The driving force behind our growth is the team of innovative professionals who share a commitment to innovation, the Novanta Growth System, and our customers’ success. Novanta’s common shares are quoted on Nasdaq under the ticker symbol “NOVT.”

More information about Novanta is available on the Company’s website at www.novanta.com. For additional information, please contact Novanta Inc. Investor Relations at (781) 266-5137 or [email protected].

More News From Novanta Inc.

Back to Newsroom

BOSTON--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) (“Novanta” or the “Company”), a trusted technology partner to medical and advanced technology equipment manufacturers, today reported financial results for the first quarter 2026.

Financial Highlights

Three Months Ended

(In millions, except per share amounts)

April 3,

March 28,

2026

2025

GAAP

Revenue

$

257.7

$

233.4

Operating Income

$

27.5

$

32.4

Net Income

$

21.1

$

21.2

Diluted EPS

$

0.51

$

0.59

Non-GAAP*

Adjusted Operating Income

$

43.2

$

39.1

Adjusted Diluted EPS

$

0.81

$

0.74

Adjusted EBITDA

$

57.1

$

50.0

*Reconciliations of GAAP to non-GAAP financial measures, as well as definitions for the non-GAAP financial measures included in this press release and the reasons for their use, are presented below.

First Quarter

“Novanta delivered another quarter of excellent bookings, growing 37% year-over-year and representing a 1.10 book-to-bill ratio, driven by continued new product momentum and strong commercial execution by our business teams,” said Matthijs Glastra, Chair and Chief Executive Officer. “We exceeded expectations with revenue growth of more than 10% year-over-year on a reported basis and 3% organically. Adjusted EBITDA advanced 14%, Adjusted Diluted EPS of $0.81 increased 9%, and Operating Cash Flow grew 63%.”

For the first quarter of 2026, Novanta generated GAAP revenue of $257.7 million, an increase of $24.3 million or 10.4%, compared to prior year. The Company’s acquisition activities resulted in a net increase in revenue of $9.0 million or 3.8%. Year-over-year changes in foreign currency exchange rates favorably impacted revenue by $8.2 million or 3.5%. Organic Revenue Growth, which excludes the net impact of acquisitions and changes in foreign currency exchange rates, was an increase of 3.1% (see “Organic Revenue Growth” in the non-GAAP reconciliations below).

For the first quarter of 2026, GAAP operating income was $27.5 million, compared to $32.4 million in the prior year. GAAP net income was $21.1 million, compared to $21.2 million in the prior year. GAAP diluted earnings per share (“EPS”) was $0.51, compared to $0.59 in the prior year. Diluted weighted average shares outstanding was 41.2 million for the first quarter of 2026.

Adjusted Diluted EPS increased 9.5% to $0.81, compared to $0.74 in the prior year. Adjusted EBITDA increased 14.2% to $57.1 million, compared to $50 million in the prior year.

Operating cash flow was $51.6 million, compared to $31.7 million in the prior year. The year-over-year increase in operating cash flow was primarily driven by improvements in net working capital.

Financial Guidance

“Strong bookings and a growing backlog support a step up to 6% to 8% organic revenue growth in the Second Quarter. We see building momentum across several of our end markets, especially in AI-driven advanced industrial and semiconductor markets, as well as advanced robotics, and minimally invasive and robotic surgery; all of which look set to compound as the year continues,” said Matthijs Glastra. “We remain confident in delivering strong organic revenue growth for the full year and rigorously executing in a dynamic trade and economic climate to drive meaningful shareholder value.”

For the second quarter of 2026, the Company expects GAAP revenue to be in the range of $259 million to $264 million. The Company expects Adjusted EBITDA to be in the range of $58 million to $62 million and Adjusted Diluted EPS to be in the range of $0.81 to $0.86. The Company’s guidance assumes no significant changes in foreign exchange rates.

For the full year 2026, the Company expects GAAP revenue to be in the range of $1,040 million to $1,055 million. The Company expects Adjusted EBITDA to be in the range of $245 million to $250 million and Adjusted Diluted EPS to be in the range of $3.50 to $3.65. The Company’s guidance assumes no significant changes in foreign exchange rates.

Novanta provides earnings guidance on a non-GAAP basis and does not provide earnings guidance on a GAAP basis, with the exception of GAAP revenue guidance. A reconciliation of the Company’s forward-looking Adjusted EBITDA and Adjusted Diluted EPS guidance to the most directly comparable GAAP financial measures is not provided because of the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliations, including acquisitions and related expenses; impact of purchase price allocations for recently completed acquisitions; future changes in the fair value of contingent considerations; future restructuring expenses; foreign exchange gains/(losses); significant discrete income tax expenses (benefits); benefits or expenses associated with the completion of tax audits; divestitures and related expenses; gains and losses from sale of real estate assets; costs related to product line closures; intangible asset impairment charges and related asset write-offs; and other charges reflected in the Company’s reconciliation of historical non-GAAP financial measures, the amounts of which, based on past experience, could be material. For additional information regarding Novanta’s non-GAAP financial measures, see “Use of Non-GAAP Financial Measures” below.

Conference Call Information

The Company will host a conference call on Tuesday, May 12, 2026 at 8:00 a.m. ET to discuss these results and to provide a business update. To access the call, please dial (888) 346-3959 prior to the scheduled conference call time. Alternatively, the conference call can be accessed online via a live webcast on the Events & Presentations page of the Investors section of the Company’s website at www.novanta.com.

A replay of the audio webcast will be available approximately three hours after the conclusion of the call in the Investor Relations section of the Company’s website at www.novanta.com. The replay will remain available until Monday, July 06, 2026.

Use of Non-GAAP Financial Measures

The non-GAAP financial measures used in this press release are Organic Revenue Growth, Adjusted Gross Profit, Adjusted Gross Profit Margin, Adjusted Operating Income, Adjusted Operating Margin, Adjusted Income Before Income Taxes, Adjusted Income Tax Provision/(Benefit) and Effective Tax Rate, Adjusted Net Income, Adjusted Diluted EPS, Adjusted EBITDA, Adjusted EBITDA Margin, Free Cash Flow, Free Cash Flow as a Percentage of Net Income, and Net Debt.

The Company believes that these non-GAAP financial measures provide useful and supplementary information to investors regarding the operating performance of the Company. It is management’s belief that these non-GAAP financial measures would be particularly useful to investors because of the significant changes that have occurred outside of the Company’s day-to-day business in accordance with the execution of the Company’s strategy. This strategy includes streamlining the Company’s existing operations through site and functional consolidations, strategic divestitures and product line closures, expanding the Company’s business through significant internal investments, and broadening the Company’s product and service offerings through acquisitions of innovative and complementary technologies and solutions. The financial impact of certain elements of these activities, particularly acquisitions, divestitures, and site and functional restructurings, is often large relative to the Company’s overall financial performance and can adversely affect the comparability of its operating results and investors’ ability to analyze the business from period to period.

The Company’s Adjusted EBITDA, Organic Revenue Growth and Adjusted Gross Profit Margin are used by management to evaluate operating performance, communicate financial results to the Board of Directors, benchmark results against historical performance and the performance of peers, and evaluate investment opportunities, including acquisitions and divestitures. In addition, Adjusted EBITDA, Organic Revenue Growth and Adjusted Gross Profit Margin are used to determine bonus payments for senior management and employees. The Company has also used in the past, and may use in the future, Adjusted Diluted EPS and Adjusted EBITDA as performance targets for certain performance-based restricted stock units. Accordingly, the Company believes that these non-GAAP financial measures provide greater transparency and insight into management’s method of analysis.

Non-GAAP financial measures should not be considered as substitutes for, or superior to, measures of financial performance prepared in accordance with GAAP. They are limited in value because they exclude charges that have a material effect on the Company’s reported results and, therefore, should not be relied upon as the sole financial measures to evaluate the Company’s financial results. The non-GAAP financial measures are meant to supplement, and to be viewed in conjunction with, GAAP financial measures. Investors are encouraged to review the reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measures as provided in the tables accompanying this press release.

Safe Harbor and Forward-Looking Information

Certain statements in this release are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and are based on current expectations and assumptions that are subject to risks and uncertainties. All statements contained in this news release that do not relate to matters of historical fact should be considered forward-looking statements, and are generally identified by words such as “expect,” “intend,” “anticipate,” “estimate,” “believe,” “future,” “target,” “could,” “should,” “may,” “plan,” “aim,” and other similar expressions. These forward-looking statements include, but are not limited to, the statements of Mr. Glastra in this press release; statements regarding anticipated financial performance and financial position, including our financial outlook for the second quarter of 2026; expectations for our future growth and prospects; expectations for our customers and for our end markets; expectations for our strategy and business model; expectations for new product launches and commercial activities; expectations with respect to productivity enhancements, expectations for margin and cash flow performance; expectations for our site regionalization strategy; expectations for capital deployment to acquisitions or other investment options; and other statements that are not historical facts.

These forward-looking statements are neither promises nor guarantees, but involve risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various important factors, including, but not limited to, the following: economic and political conditions and the effects of these conditions on our businesses and on our customers’ businesses, capital expenditures and level of business activities; our dependence upon our ability to respond to fluctuations in product demand; our ability to continuously innovate, to introduce new products in a timely manner, and to manage transitions to new product innovations effectively; customer order timing and other similar factors; disruptions or breaches in security of our or our third-party providers’ information technology systems; risks associated with our operations in foreign countries; our increased use of outsourcing in foreign countries; risks associated with increased outsourcing of components manufacturing; our exposure to increased tariffs, trade restrictions or taxes on our products; our ability to contain or reduce costs; violations of our intellectual property rights and our ability to protect our intellectual property against infringement by third parties; risk of losing our competitive advantage; our failure to successfully integrate recent and future acquisitions into our business; our ability to attract and retain key personnel; our restructuring and realignment activities; product defects or problems integrating our products with other vendors’ products; disruptions in the supply of certain key components and other goods from our suppliers; our failure to accurately forecast component and raw material requirements leading to additional costs and significant delays in shipments; production difficulties and product delivery delays or disruptions; our exposure to extensive medical device regulations, which may impede or hinder the approval, certification or sale of our products and, in some cases, may ultimately result in an inability to obtain approval or certification of certain products or may result in the recall or seizure of previously approved or certified products; potential penalties for violating foreign and U.S. federal and state healthcare laws and regulations; impact of healthcare industry cost containment and healthcare reform measures; changes in governmental regulations related to our business or products; actual or perceived failures to comply with applicable data protection, privacy and security laws, regulations, standards, and other requirements; our failure to implement new information technology systems successfully; changes in foreign currency rates; our failure to realize the full value of our intangible assets; our reliance on original equipment manufacturer customers; the loss of sales, or significant reduction in orders from, any major customers; increasing scrutiny and changing expectations from investors, customers, governments and other stakeholders and third parties with respect to corporate sustainability policies and practices; the effects of climate change and related regulatory responses; our exposure to the credit risk of some of our customers and in weakened markets; being subject to U.S. federal income taxation even though we are a non-U.S. corporation; changes in tax laws and fluctuations in our effective tax rates; any need for additional capital to adequately respond to business challenges or opportunities and repay or refinance our existing indebtedness, which may not be available on acceptable terms or at all; our existing indebtedness limiting our ability to engage in certain activities; volatility in the market price for our common shares; and our failure to maintain appropriate internal controls in the future.

Other important risk factors that could affect the outcome of the events set forth in these statements and that could affect the Company’s operating results and financial condition are discussed in Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended December 31, 2025, as updated by our subsequent filings with the Securities and Exchange Commission. Such statements are based on the Company’s beliefs and assumptions and on information currently available to the Company. The Company disclaims any obligation to publicly update or revise any such forward-looking statements as a result of developments occurring after the date of this document except as required by law.

About Novanta

Novanta is a leading global supplier of core technology solutions that give medical, life science, and advanced industrial original equipment manufacturers a competitive advantage. We combine deep proprietary expertise and competencies in precision medicine, precision manufacturing, robotics and automation, and advanced surgery with a proven ability to solve complex technical challenges. This enables Novanta to engineer proprietary technology solutions that deliver extreme precision and performance, tailored to our customers' demanding applications. The driving force behind our growth is the team of innovative professionals who share a commitment to innovation, the Novanta Growth System, and our customers’ success. Novanta’s common shares are quoted on Nasdaq under the ticker symbol “NOVT.”

More information about Novanta is available on the Company’s website at www.novanta.com. For additional information, please contact Novanta Investor Relations at (781) 266-5137 or [email protected].

NOVANTA INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands of U.S. dollars or shares, except per share amounts)

(Unaudited)

  Three Months Ended

April 3,

March 28,

2026

2025

Revenue

$

257,707

$

233,366

Cost of revenue

144,129

129,012

Gross profit

113,578

104,354

Operating expenses:

Research and development and engineering

23,251

23,238

Selling, general and administrative

54,409

45,596

Amortization of purchased intangible assets

5,774

5,554

Restructuring, acquisition, and related costs

2,605

(2,455

)

Total operating expenses

86,039

71,933

Operating income

27,539

32,421

Interest income (expense), net

(1,843

)

(5,644

)

Foreign exchange transaction gains (losses), net

731

(368

)

Other income (expense), net

(73

)

9

Income before income taxes

26,354

26,418

Income tax provision (benefit)

5,255

5,210

Net Income

$

21,099

$

21,208

Earnings per common share:

Basic

$

0.52

$

0.59

Diluted

$

0.51

$

0.59

Weighted average common shares outstanding—basic

40,425

36,024

Weighted average common shares outstanding—diluted

41,158

36,130

NOVANTA INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands of U.S. dollars)

(Unaudited)

  April 3,

December 31,

2026

2025

ASSETS

Current Assets

Cash and cash equivalents

$

388,799

$

380,871

Accounts receivable, net

173,934

184,880

Inventories

193,143

188,284

Prepaid expenses and other current assets

30,927

28,566

Total current assets

786,803

782,601

Property, plant and equipment, net

116,961

118,491

Operating lease assets

40,361

41,697

Intangible assets, net

170,299

180,776

Goodwill

643,379

647,348

Other assets

41,252

36,193

Total assets

$

1,799,055

$

1,807,106

LIABILITIES AND STOCKHOLDERS’ EQUITY

Current Liabilities

Current portion of long-term debt

$

40,416

$

38,291

Accounts payable

96,203

94,865

Accrued expenses and other current liabilities

84,173

79,211

Total current liabilities

220,792

212,367

Long-term debt

201,005

212,538

Operating lease liabilities

37,244

38,873

Other long-term liabilities

28,986

29,041

Total liabilities

488,027

492,819

Stockholders’ Equity:

Total stockholders’ equity

1,311,028

1,314,287

Total liabilities and stockholders’ equity

$

1,799,055

$

1,807,106

NOVANTA INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands of U.S. dollars)

(Unaudited)

  Three Months Ended

April 3,

March 28,

2026

2025

Cash flows from operating activities:

Net Income

$

21,099

$

21,208

Adjustments to reconcile net income to net cash provided by operating activities:

Depreciation and amortization

14,160

13,563

Share-based compensation

9,796

7,100

Deferred income taxes

(2,877

)

(2,393

)

Loss (gain) on disposal of fixed assets

(248

)

(4,367

)

Other

1,749

1,150

Changes in assets and liabilities which (used)/provided cash, excluding effects from business acquisitions:

Accounts receivable

9,703

(12,188

)

Inventories

(6,827

)

(61

)

Other operating assets and liabilities

5,051

7,672

Net cash provided by operating activities

51,606

31,684

Cash flows from investing activities:

Purchases of property, plant and equipment

(4,138

)

(4,284

)

Proceeds from sale of property, plant and equipment

345

5,537

Net cash (used in) provided by investing activities

(3,793

)

1,253

Cash flows from financing activities:

Repayments of debt

(8,800

)

(29,719

)

Payments of issuance costs related to tangible equity units

(1,293

)

—

Payments of withholding taxes from share-based awards

(6,982

)

(6,669

)

Repurchases of common shares

(18,638

)

(6,157

)

Payments of contingent consideration related to acquisitions

(4,393

)

—

Other financing activities

(16

)

(186

)

Net cash used in financing activities

(40,122

)

(42,731

)

Effect of exchange rates on cash and cash equivalents

237

1,850

Increase (decrease) in cash and cash equivalents

7,928

(7,944

)

Cash and cash equivalents, beginning of period

380,871

113,989

Cash and cash equivalents, end of period

$

388,799

$

106,045

NOVANTA INC.

Revenue by Reportable Segment

(In thousands of U.S. dollars)

(Unaudited)

  Three Months Ended

April 3,

March 28,

2026

2025

Revenue

Automation Enabling Technologies

$

131,244

$

123,167

Medical Solutions

126,463

110,199

Total

$

257,707

$

233,366

NOVANTA INC.

Reconciliation of GAAP to Non-GAAP Financial Measures

(In thousands of U.S. dollars)

(Unaudited)

   Adjusted Gross Profit and Adjusted Gross Profit Margin by Reportable Segment (Non-GAAP):

  Three Months Ended

April 3,

March 28,

2026

2025

Automation Enabling Technologies

Gross Profit (GAAP)

$

62,751

$

59,386

Gross Profit Margin (GAAP)

47.8

%

48.2

%

Amortization of intangible assets

1,201

1,359

Operational transformation costs

18

—

Adjusted Gross Profit (Non-GAAP)

$

63,970

$

60,745

Adjusted Gross Profit Margin (Non-GAAP)

48.7

%

49.3

%

Medical Solutions

Gross Profit (GAAP)

$

52,175

$

45,961

Gross Profit Margin (GAAP)

41.3

%

41.7

%

Amortization of intangible assets

2,558

2,202

Operational transformation costs

170

—

Adjusted Gross Profit (Non-GAAP)

$

54,903

$

48,163

Adjusted Gross Profit Margin (Non-GAAP)

43.4

%

43.7

%

Unallocated

Gross Profit (GAAP)

$

(1,348

)

$

(993

)

Operational transformation costs

37

—

Adjusted Gross Profit (Non-GAAP)

$

(1,311

)

$

(993

)

Novanta Inc.

Gross Profit (GAAP)

$

113,578

$

104,354

Gross Profit Margin (GAAP)

44.1

%

44.7

%

Amortization of intangible assets

3,759

3,561

Operational transformation costs

225

—

Adjusted Gross Profit (Non-GAAP)

$

117,562

$

107,915

Adjusted Gross Profit Margin (Non-GAAP)

45.6

%

46.2

%

NOVANTA INC.

Reconciliation of GAAP to Non-GAAP Financial Measures

(Amounts in thousands except per share amounts)

(Unaudited)

   Adjusted Operating Income and Adjusted Diluted EPS (Non-GAAP):

  Three Months Ended April 3, 2026

Operating Income

Operating Margin

Income Before Income Taxes

Income Tax Provision / (Benefit)

Effective Tax Rate

Net Income

Diluted EPS

GAAP results

$

27,539

10.7

%

$

26,354

$

5,255

19.9

%

$

21,099

$

0.51

Non-GAAP Adjustments:

Amortization of intangible assets

9,533

3.7

%

9,533

Restructuring costs

1,525

0.6

%

1,525

Acquisition and related costs

1,080

0.4

%

1,080

Planning and design phase of the financial and operation system implementation

2,658

1.0

%

2,658

Operational transformation costs

556

0.2

%

556

EU medical device regulation charges

269

0.1

%

269

Foreign exchange transaction (gains) losses, net

(731

)

Tax effect of non-GAAP adjustments

3,359

Non-GAAP tax adjustments

(752

)

Total non-GAAP adjustments

15,621

6.0

%

14,890

2,607

12,283

0.30

Adjusted results (Non-GAAP)

$

43,160

16.7

%

$

41,244

$

7,862

19.1

%

$

33,382

$

0.81

Weighted average shares outstanding - Diluted

41,158

NOVANTA INC.

Reconciliation of GAAP to Non-GAAP Financial Measures

(Amounts in thousands except per share amounts)

(Unaudited)

   Adjusted Operating Income and Adjusted Diluted EPS (Non-GAAP):

  Three Months Ended March 28, 2025

Operating Income

Operating Margin

Income Before Income Taxes

Income Tax Provision / (Benefit)

Effective Tax Rate

Net Income

Diluted EPS

GAAP results

$

32,421

13.9

%

$

26,418

$

5,210

19.7

%

$

21,208

$

0.59

Non-GAAP Adjustments:

Amortization of intangible assets

9,115

3.9

%

9,115

Restructuring costs

(3,005

)

(1.3

)%

(3,005

)

Acquisition and related costs

550

0.2

%

550

Foreign exchange transaction (gains) losses, net

368

Tax effect of non-GAAP adjustments

1,006

Non-GAAP tax adjustments

446

Total non-GAAP adjustments

6,660

2.8

%

7,028

1,452

5,576

0.15

Adjusted results (Non-GAAP)

$

39,081

16.7

%

$

33,446

$

6,662

19.9

%

$

26,784

$

0.74

Weighted average shares outstanding - Diluted

36,130

NOVANTA INC.

Reconciliation of GAAP to Non-GAAP Financial Measures

(In thousands of U.S. dollars)

(Unaudited)

   Adjusted EBITDA (Non-GAAP):

  Three Months Ended

April 3,

March 28,

2026

2025

Net Income (GAAP)

$

21,099

$

21,208

Net Income Margin

8.2

%

9.1

%

Interest (income) expense, net

1,843

5,644

Income tax provision (benefit)

5,255

5,210

Depreciation and amortization

14,160

13,563

Share-based compensation

9,796

7,100

Restructuring, acquisition and related costs(1)

2,098

(3,106

)

Planning and design phase of the financial and operation system implementation

2,658

—

Operational transformation costs

556

—

EU medical device regulation charges

269

—

Other, net

(658

)

359

Adjusted EBITDA (Non-GAAP)

$

57,076

$

49,978

Adjusted EBITDA Margin (Non-GAAP)

22.1

%

21.4

%

Organic Revenue Growth (Non-GAAP):

  Three Months Ended April 3, 2026

Compared to

Three Months Ended March 28, 2025

Reported Revenue Growth/(Decline) (GAAP)

10.4

%

Less: Change attributable to acquisitions

3.8

%

Plus: Change due to foreign currency

(3.5

)%

Organic Revenue Growth/(Decline) (Non-GAAP)

3.1

%

Net Debt (Non-GAAP):

  April 3,

December 31,

2026

2025

Total Debt (GAAP)

$

241,421

$

250,829

Plus: Deferred financing costs

8,008

8,726

Gross Debt

249,429

259,555

Less: Cash and cash equivalents

(388,799

)

(380,871

)

Net Debt (Non-GAAP)

$

(139,370

)

$

(121,316

)

Free Cash Flow (Non-GAAP):

  Three Months Ended

April 3,

March 28,

2026

2025

Net Cash Provided by Operating Activities (GAAP)

$

51,606

$

31,684

Less: Purchases of property, plant and equipment

(4,138

)

(4,284

)

Plus: Proceeds from sale of property, plant and equipment

345

5,537

Free Cash Flow (Non-GAAP)

$

47,813

$

32,937

Net Income (GAAP)

$

21,099

$

21,208

Net Cash Provided by Operating Activities as a Percentage of Net Income

244.6

%

149.4

%

Free Cash Flow as a Percentage of Net Income

226.6

%

155.3

%

Non-GAAP Financial Measures

The following provides additional explanations for non-GAAP financial measures used by the Company, including explanations for certain non-GAAP adjustments that may not be present in the quarterly disclosures included in the current earnings release but have been used by the Company in the two most recent fiscal years. See the tables above for the calculations of the non-GAAP financial measures used in this earnings release.

Organic Revenue Growth

The Company defines the term “organic revenue” as revenue excluding the impact from business acquisitions, divestitures, product line discontinuations, and the effect of foreign currency translation. The Company uses the related term “organic revenue growth” to refer to the financial performance metric of comparing current period organic revenue with the reported revenue of the corresponding period in the prior year. The Company believes that this non-GAAP financial measure, when taken together with our GAAP financial measures, allows the Company and its investors to better measure the Company’s performance and evaluate long-term performance trends. Organic revenue growth also facilitates easier comparisons of the Company’s performance with prior and future periods and relative comparisons to its peers. The Company excludes the effect of foreign currency translation from these measures because foreign currency translation is subject to volatility and can obscure underlying business trends. The Company excludes the effect of acquisitions and divestitures because these activities can vary dramatically between reporting periods and between the Company and its peers, which the Company believes makes comparisons of long-term performance trends difficult for management and investors. Organic Revenue Growth is also used as a performance metric to determine bonus payments for senior management and employees.

Adjusted Gross Profit and Adjusted Gross Profit Margin

The calculation of Adjusted Gross Profit and Adjusted Gross Profit Margin excludes amortization of acquired intangible assets, inventory fair value adjustments related to business acquisitions, and inventory related charges associated with product line closures because: (i) the amounts are non-cash; (ii) the Company cannot influence the timing and amount of future expense recognition; and (iii) excluding such expenses provides investors and management better visibility into the underlying trends and performance of our businesses. The Company also excludes inventory related charges associated with product line closures and operational transformation costs as these costs occurred outside of the Company’s day-to-day business for the reasons described above in the introductory paragraphs of the “Use of Non-GAAP Financial Measures.”

Adjusted Operating Income and Adjusted Operating Margin

The calculation of Adjusted Operating Income and Adjusted Operating Margin excludes amortization of acquired intangible assets, inventory fair value adjustments related to business acquisitions, inventory related charges associated with product line closures, and operational transformation costs for the reasons described above for Adjusted Gross Profit and Adjusted Gross Profit Margin. The Company also excludes restructuring costs, acquisition and related costs, discrete costs related to the planning and design phase of a Financial and Operation system implementation, charges related to an insurance recovery, officer transition costs, and EU medical device regulation charges as the significant charges have occurred outside of the Company’s day-to-day business for the reasons described above in the introductory paragraphs of the “Use of Non-GAAP Financial Measures.”

Adjusted Income Before Income Taxes

The calculation of Adjusted Income Before Income Taxes excludes amortization of acquired intangible assets, inventory fair value adjustments related to business acquisitions, inventory related charges associated with product line closures, operational transformation costs, restructuring, acquisition and related costs, discrete costs related to the planning and design phase of a Financial and Operation system implementation, charges related to an insurance recovery, officer transition costs, and EU medical device regulation charges for Adjusted Operating Income and Adjusted Operating Margin. The Company also excludes foreign exchange transaction gains (losses) as well as the write-off of costs related to our debt refinancing from the calculation of Adjusted Income Before Income Taxes as the Company cannot fully influence the timing and amount of foreign exchange transaction gains (losses).

Non-GAAP Income Tax Provision/(Benefit) and Effective Tax Rate

Non-GAAP Income Tax Provision/(Benefit) and Effective Tax Rate are calculated based on the Adjusted Income Before Income Taxes by jurisdiction, the applicable tax rates in effect for the respective jurisdictions and the income tax effect of non-GAAP adjustments discussed above. In addition, the Company excludes significant discrete income tax expenses (benefits) related to releases of valuation allowances and uncertain tax positions not related to current year activity, tax audits, certain changes in tax laws, and acquisition related tax planning actions on the Company’s effective tax rate.

Adjusted Net Income

Because Income Before Income Taxes is included in determining Net Income, the calculation of Adjusted Net Income also excludes amortization of acquired intangible assets, inventory fair value adjustments related to business acquisitions, inventory related charges associated with product line closures, operational transformation costs, restructuring, acquisition and related costs, discrete costs related to the planning and design phase of a Financial and Operation system implementation, charges related to an insurance recovery, officer transition costs, EU medical device regulation charges, write-off of costs related to our debt refinancing, and foreign exchange transaction gains (losses) for the reasons described above for Adjusted Income Before Income Taxes. In addition, the Company excludes (i) significant discrete income tax expenses (benefits) related to releases of valuation allowances and uncertain tax positions, tax audits or amendments to prior year returns, certain changes in tax laws, and acquisition related tax planning actions on the Company’s effective tax rate; and (ii) the income tax effect of non-GAAP adjustments discussed above.

Adjusted Diluted EPS

Because Net Income is used in the calculation of Diluted EPS, Adjusted Diluted EPS excludes: (i) amortization of acquired intangible assets; (ii) inventory fair value adjustments related to business acquisitions; (iii) inventory related charges associated with product line closures; (iv) operational transformation costs; (v) restructuring, acquisition and related costs; (vi) discrete costs related to the planning and design phase of a Financial and Operation system implementation; (vii) officer transition costs; (viii) charges related to an insurance recovery; (ix) EU medical device regulation charges; (x) write-off of costs related to our debt refinancing (xi) foreign exchange transaction gains (losses); (xii) significant discrete income tax expenses (benefits) related to releases of valuation allowances, uncertain tax positions, tax audits or amendments to prior year returns, certain changes in tax laws, and acquisition related tax planning actions on the Company’s effective tax rate; and (xiii) the income tax effect of non-GAAP adjustments for the reasons described above for Adjusted Net Income.

Adjusted EBITDA and Adjusted EBITDA Margin

The Company defines Adjusted EBITDA as income before deducting interest (income) expense, income tax provision (benefit), depreciation, amortization, non-cash share-based compensation, inventory fair value adjustments related to business acquisitions, inventory related charges associated with product line closures, restructuring, acquisition and related costs, discrete costs related to the planning and design phase of a Financial and Operation system implementation, charges related to an insurance recovery, officer transition costs, operational transformation costs, EU medical device regulation charges, and other non-operating (income) expense items, including foreign exchange transaction (gains) losses, costs related to our debt refinancing and net periodic pension costs of the Company’s frozen U.K. defined benefit pension plan for the reasons described above in the introductory paragraphs of the “Use of Non-GAAP Financial Measures.”

Adjusted EBITDA Margin is defined as Adjusted EBITDA as a percentage of Revenue.

In evaluating Adjusted EBITDA and Adjusted EBITDA Margin, you should be aware that in the future the Company may incur expenses that are the same as, or similar to, some of the adjustments in this presentation.

Free Cash Flow and Free Cash Flow as a Percentage of Net Income

The Company defines Free Cash Flow as net cash provided by operating activities less cash paid for purchases of property, plant and equipment and plus cash proceeds from sales of property, plant and equipment. Free Cash Flow as a Percentage of Net Income is defined as Free Cash Flow divided by Net Income. Management believes these non-GAAP financial measures are important indicators of the Company’s liquidity as well as its ability to service its outstanding debt and to fund future growth.

Net Debt

The Company defines Net Debt as its total debt as reported on the consolidated balance sheet plus unamortized deferred financing costs and less its cash and cash equivalents as of the end of the period presented. Management uses Net Debt to monitor the Company’s outstanding debt obligations that could not be satisfied by its cash and cash equivalents on hand.

More News From Novanta Inc.

2 hours ago

MSA Safety Incorporporated (NYSE:MSA) CFO Acquires $71,093.12 in StockMarketBeat

MSA Safety Incorporporated (NYSE:MSA - Get Free Report) CFO Julie Beck bought 448 shares of the stock in a transaction dated Thursday, June 11th. The stock was acquired at an average price of $158.69 per share, with a total value of $71,093.12. Following the completion of the purchase, the chief financial officer owned 3,825 shares of the company's stock, valued at $606,989.25. This represents a 13.27% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

NYSE:MSA

Read MSA Safety Incorporporated (NYSE:MSA) CFO Acquires $71,093.12 in Stock

2 hours ago

Insider Selling: NBT Bancorp (NASDAQ:NBTB) Director Sells 2,100 Shares of StockMarketBeat

NBT Bancorp Inc. (NASDAQ:NBTB - Get Free Report) Director Heidi Hoeller sold 2,100 shares of the business's stock in a transaction that occurred on Friday, June 12th. The shares were sold at an average price of $48.03, for a total transaction of $100,863.00. Following the transaction, the director owned 11,560 shares of the company's stock, valued at approximately $555,226.80. This represents a 15.37% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

NASDAQ:NBTB

Read Insider Selling: NBT Bancorp (NASDAQ:NBTB) Director Sells 2,100 Shares of Stock

2 hours ago

Douglas Milne Sells 1,600 Shares of IGM Financial (TSE:IGM) StockMarketBeat

IGM Financial Inc. (TSE:IGM - Get Free Report) Director Douglas Milne sold 1,600 shares of the business's stock in a transaction that occurred on Tuesday, June 9th. The stock was sold at an average price of C$80.61, for a total value of C$128,976.00. Following the sale, the director directly owned 800 shares in the company, valued at C$64,488. The trade was a 66.67% decrease in their ownership of the stock.

TSE:IGM

Read Douglas Milne Sells 1,600 Shares of IGM Financial (TSE:IGM) Stock

2 hours ago

GlobalFoundries (NASDAQ:GFS) Insider Michael James Hogan Sells 2,800 SharesMarketBeat

GlobalFoundries Inc. (NASDAQ:GFS - Get Free Report) insider Michael James Hogan sold 2,800 shares of GlobalFoundries stock in a transaction on Wednesday, June 10th. The shares were sold at an average price of $75.17, for a total value of $210,476.00. Following the transaction, the insider owned 6,695 shares in the company, valued at $503,263.15. This trade represents a 29.49% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

NASDAQ:GFS

Read GlobalFoundries (NASDAQ:GFS) Insider Michael James Hogan Sells 2,800 Shares

Sort By

Time Frame

Alert Type

Keywords

Page 1 of 325

-

BOSTON--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) (the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, announced today that Robert Buckley, Chief Financial Officer, is scheduled to present at Baird 2026 Global Consumer, Technology & Services Conference on Wednesday, June 3, 2026, in New York, NY.

About Novanta

Novanta is a leading global supplier of core technology solutions that give medical, life science, and advanced industrial original equipment manufacturers a competitive advantage. We combine deep proprietary expertise and competencies in precision medicine, precision manufacturing, robotics and automation, and advanced surgery with a proven ability to solve complex technical challenges. This enables Novanta to engineer proprietary technology solutions that deliver extreme precision and performance, tailored to our customers' demanding applications. The driving force behind our growth is the team of innovative professionals who share a commitment to innovation, the Novanta Growth System, and our customers’ success. Novanta’s common shares are quoted on Nasdaq under the ticker symbol “NOVT.”

More information about Novanta is available on the Company’s website at www.novanta.com. For additional information, please contact Novanta Inc. Investor Relations at (781) 266-5137 or [email protected].

More News From Novanta Inc.

Back to Newsroom

The price trend for Novanta (NOVT - Free Report) has been bearish lately and the stock has lost 7.3% over the past week. However, the formation of a hammer chart pattern in its last trading session indicates that the stock could witness a trend reversal soon, as bulls might have gained significant control over the price to help it find support.

While the formation of a hammer pattern is a technical indication of nearing a bottom with potential exhaustion of selling pressure, rising optimism among Wall Street analysts about the future earnings of this photonic and motion control components maker is a solid fundamental factor that enhances the prospects of a trend reversal for the stock.

Understanding Hammer Chart and the Technique to Trade ItThis is one of the popular price patterns in candlestick charting. A minor difference between the opening and closing prices forms a small candle body, and a higher difference between the low of the day and the open or close forms a long lower wick (or vertical line). The length of the lower wick being at least twice the length of the real body, the candle resembles a 'hammer.'

In simple terms, during a downtrend, with bears having absolute control, a stock usually opens lower compared to the previous day's close, and again closes lower. On the day the hammer pattern is formed, maintaining the downtrend, the stock makes a new low. However, after eventually finding support at the low of the day, some amount of buying interest emerges, pushing the stock up to close the session near or slightly above its opening price.

When it occurs at the bottom of a downtrend, this pattern signals that the bears might have lost control over the price. And, the success of bulls in stopping the price from falling further indicates a potential trend reversal.

Hammer candles can occur on any timeframe -- such as one-minute, daily, weekly -- and are utilized by both short-term as well as long-term investors.

Like every technical indicator, the hammer chart pattern has its limitations. Particularly, as the strength of a hammer depends on its placement on the chart, it should always be used in conjunction with other bullish indicators.

Here's What Increases the Odds of a Turnaround for NOVTAn upward trend in earnings estimate revisions that NOVT has been witnessing lately can certainly be considered a bullish indicator on the fundamental side. That's because empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.

The consensus EPS estimate for the current year has increased 1.3% over the last 30 days. This means that the Wall Street analysts covering NOVT are majorly in agreement about the company's potential to report better earnings than what they predicted earlier.

If this is not enough, you should note that NOVT currently has a Zacks Rank #2 (Buy), which means it is in the top 20% of more than 4,000 stocks that we rank based on trends in earnings estimate revisions and EPS surprises. And stocks carrying a Zacks Rank #1 or 2 usually outperform the market. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .

Moreover, a Zacks Rank of 2 for Novanta is a more conclusive indication of a potential trend reversal, as the Zacks Rank has proven to be an excellent timing indicator that helps investors identify precisely when a company's prospects are beginning to improve.

On May 22, 2026, Novanta Inc NOVT shares rose 3.1% to $159.70, reflecting a positive price movement amid a strong performance over the past month and year. The stock has fluctuated between a 52-week high of $165.56 and a low of $98.27, showcasing significant volatility.

GF Value™ verdict: The current price of $159.70 is 3.6% above the GF Value™ of $154.22, indicating the stock is overvalued.GF Score™ of 89/100 suggests a strong overall performance, highlighting its potential for long-term returns.Insider activity shows that insiders sold $4.9 million worth of stock in the last three months, which may indicate a lack of confidence in the current price level. Is NOVT Overvalued or Undervalued? Currently, Novanta Inc NOVT is trading at $159.70, which is 3.6% higher than its GF Value™ estimate of $154.22. This indicates that the stock is overvalued, presenting a potential risk to investors who may be considering entering the position. The GF Valuation label categorizes NOVT as fairly valued, but given the current price exceeds the intrinsic value, it emphasizes a lack of margin of safety for new investments.

GF Value™ is GuruFocus' proprietary measure of intrinsic value, calculated from historical trading multiples, past business growth, and future performance estimates. An overvalued stock can carry risks, particularly in volatile markets where price corrections are common.

How Does NOVT's Valuation Compare to Its History? MetricCurrentHistorical P/E (TTM)115.7x81.3x Forward P/E44.5x- The current P/E ratio of 115.7x is significantly higher than the 5-year median P/E of 81.3x, indicating that NOVT is trading at a premium compared to its historical valuation. With the current P/E being 42% above its historical median, the P/E analysis supports the GF Value™ verdict that the stock is overvalued.

What Does NOVT's GF Score™ Tell Us? MetricRating GF Score™89/100 Financial Strength8/10 Profitability9/10 Growth6/10 Valuation9/10 Momentum8/10 Novanta Inc's GF Score™ of 89/100 reflects a strong performance across several key areas. The company excels in Profitability with a score of 9/10 and demonstrates solid Financial Strength, rated at 8/10. However, its Growth Rank of 6/10 suggests that there are areas for improvement in terms of expanding its revenue and market footprint. Overall, the high GF Score™ indicates that NOVT is well-positioned for long-term success, despite its current overvaluation.

What Are Insiders Doing with NOVT Stock? In the last three months, insider activity has seen a total of $4.9 million in shares sold, with no reported buying activity. This trend of selling may signal a lack of confidence among insiders regarding the stock's current valuation level or future growth prospects. When insiders sell significant amounts of stock, it can raise concerns about their outlook on the company’s performance and may warrant caution among potential investors.

What This Means for Investors Based on the GF Value™ assessment, Novanta Inc NOVT is currently overvalued at a price of $159.70, which is above its estimated fair value of $154.22. While the company shows strong potential through its high GF Score™, investors should be cautious given the stock's current price relative to its intrinsic value.

For the complete analysis, visit the Novanta Inc NOVT stock page. You can also explore the GF Value™ page for detailed valuation methodology, or use the GuruFocus Stock Screener to find similar opportunities.

Frequently Asked Questions What is NOVT's GF Score™?

NOVT has a GF Score™ of 89/100, indicating a strong overall performance and potential for higher long-term returns based on historical data.

Is NOVT overvalued or undervalued?

NOVT is currently overvalued, with a market price of $159.70, which exceeds the GF Value™ estimate of $154.22 by 3.6%.

What is NOVT's P/E ratio?

NOVT's P/E ratio (TTM) is 115.7x, which is significantly above its 5-year median P/E of 81.3x, suggesting the stock is trading at a premium compared to its historical valuation.

This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].

BOSTON--(BUSINESS WIRE)--Novanta Inc. (NASDAQ: NOVT) (“Novanta” or the “Company”), a trusted technology partner to leading global medical and industrial original equipment manufacturers (OEMs), today announced that it has entered into a definitive agreement to acquire Riverpoint Medical (“Riverpoint Medical” or “Riverpoint”), a category leader in high-growth minimally invasive surgical consumables, from Arlington Capital Partners (“Arlington”), a Washington D.C.-area private investment firm. Under the terms of the agreement, Novanta will acquire all outstanding equity interests of the parent company of Riverpoint Medical for an upfront cash consideration of $1.2 billion and a milestone payment of $250 million in the first quarter of 2027. The transaction is expected to close in the third quarter of 2026, subject to customary regulatory approvals and closing conditions.

The transaction is aligned with Novanta’s strategy to shift its portfolio to more durable, recurring revenue streams, which will help further reduce business cyclicality, deepen Novanta’s medical OEM partnerships, and help compound and accelerate revenue and cash flows.

Riverpoint Medical is a leading developer, designer, and manufacturer of medical devices focused on advanced surgical fibers and related technologies, providing strategic OEMs with private-label minimally invasive surgical consumables and instruments across high-growth end markets including sports medicine, trauma and cardiovascular surgery. Riverpoint’s portfolio includes unique implants and constructs requiring complex assemblies, and novel IP-protected coatings for absorbable and non-absorbable implant material.

“Riverpoint Medical is an exceptional business, a market leader in high-growth minimally invasive surgical consumables that is perfectly aligned with our strategic direction and our business model,” said Matthijs Glastra, Chair and Chief Executive Officer of Novanta. “Riverpoint Medical is growing revenue and cash flows at twice the rate of Novanta, with an expected long-term annual revenue growth outlook of 12% to 15%. Together with Novanta's core business, this acquisition is projected to double our recurring medical consumables revenue to approximately $300 million, deepen our medical end-market concentration to 60% of total revenue, and meaningfully accelerate revenue and profit growth. Because Novanta and Riverpoint serve a common customer base, we will be able to deepen those relationships while adding an additional addressable market opportunity of $2 billion. Beyond the core transaction, we expect this will meaningfully advance our regional manufacturing footprint, placing FDA-registered production capacity in the markets our customers serve, reducing supply chain risk and improving responsiveness. Riverpoint is the right fit, at the right time, and Novanta is the right owner.”

"Novanta is the ideal partner for Riverpoint Medical and for the customers we serve," said Doug King, Chief Executive Officer of Riverpoint Medical. "We have built a uniquely capable business that serves as the innovation engine behind some of the most important new product development programs of our OEM customers in sports medicine, trauma and cardiovascular surgery, utilizing highly specialized implantable surgical fibers. Joining Novanta will accelerate our strategy, while giving our customers access to a broader suite of surgical solutions through a single, deeply trusted OEM partner. We are thankful to Arlington for their strong partnership in guiding us to this point and are excited about the opportunities and resources Novanta will provide our team going forward, giving them the resources and operational infrastructure to scale faster and expand into adjacencies. We are proud of what Riverpoint has accomplished but are more excited about what we will create together."

Matt Altman, a Managing Partner at Arlington, said, “When we first partnered with Riverpoint, we recognized a company with exceptional engineering talent and differentiated capabilities in surgical fiber and biomedical textiles. Together with the management team, we’ve meaningfully expanded its product portfolio, scaled its manufacturing, and broadened its end markets. Novanta is the ideal home for Riverpoint's next chapter, and we're confident the combination will accelerate innovation for customers and create lasting opportunities for the team.” Gordon Auduong, a Managing Director at Arlington, added, “Riverpoint exemplifies the kind of business we set out to build at Arlington—mission-critical products, deep technical capability, and a culture of innovation. We’re proud of what this team has accomplished and excited to see Riverpoint join Novanta, a strategic partner with the scale and resources to take its technologies to the next level.”

Transaction details and financial impact

The upfront purchase price of $1.2 billion represents approximately 19x Riverpoint’s estimated 2026 Adjusted EBITDA excluding synergies, or approximately 17x estimated 2026 Adjusted EBITDA, including the full value of expected year-5 pro forma synergies.

Under Novanta’s ownership upon closing, Riverpoint is expected to generate Adjusted EBITDA, including synergies, of approximately $80 million in 2027. In addition, Novanta has identified more than $80 million in potential cumulative profit and cash flow synergies over five years after closing. Upon completion of the transaction, Riverpoint Medical will be reported under Novanta’s Medical Solutions operating segment.

The transaction will be financed through a combination of cash on hand and Novanta’s existing credit facility, and the recently completed $300 million equity raise.

The transaction is expected to be immediately accretive in 2026 to Novanta’s Adjusted Diluted Earnings Per Share, and in 2027 accretive to revenue growth rate, Adjusted Gross and EBITDA Margins, Adjusted Diluted Earnings Per Share, and Operating Cash Flows. Novanta expects its net leverage ratio to be approximately 2.7x (less than 3.0x on a gross leverage basis) after closing the transaction in the Third Quarter 2026. Novanta expects to reduce its net leverage ratio to be below 2.3x by year-end 2027.

The Company notes that it confirms its previously issued Second Quarter and Full Year 2026 financial guidance for the standalone Company and will update guidance for the impact of the Riverpoint acquisition once the transaction is closed.

Advisors

Baird and J.P. Morgan Securities LLC served as financial advisors to Novanta. Ropes & Gray LLP and King & Spalding LLP served as Novanta’s legal advisors in connection with the transaction. Jefferies LLC served as sole financial advisor to Riverpoint Medical and Goodwin Procter LLP served as Riverpoint Medical’s legal advisor.

About Novanta

Novanta is a leading global supplier of core technology solutions that give medical, life science, and advanced industrial original equipment manufacturers a competitive advantage. We combine deep proprietary expertise and competencies in precision medicine, precision manufacturing, robotics and automation, and advanced surgery with a proven ability to solve complex technical challenges. This enables Novanta to engineer proprietary technology solutions that deliver extreme precision and performance, tailored to our customers' demanding applications. The driving force behind our growth is the team of innovative professionals who share a commitment to innovation, the Novanta Growth System, and our customers’ success. Novanta’s common shares are quoted on Nasdaq under the ticker symbol “NOVT.” For more information, visit www.novanta.com.

About Riverpoint Medical

Riverpoint Medical is a category leader in high-growth minimally invasive surgical consumables, designing and manufacturing IP-protected, private-label products for leading medical OEM customers. Riverpoint’s portfolio includes suture anchors, implantable materials, sutures, and surgical instruments, primarily serving sports medicine and cardiovascular surgery applications. The company’s differentiated position is built on proprietary material science and coating technologies, including osteoconductive materials and coatings, and its ability to own the 510(k) clearance process end-to-end for its customers. Riverpoint is headquartered in Portland, Oregon U.S.A., with manufacturing operations in Portland, Oregon and San Jose, Costa Rica. For more information, visit www.rpmed.com.

About Arlington Capital Partners

Arlington Capital Partners is a Washington, D.C.-area private investment firm specializing in government-regulated industries. Focused on the healthcare, aerospace and defense, and government services and technology sectors, the firm partners with founders and entrepreneurs to build platforms of strategic importance to national priorities. Operating in markets with high barriers to entry, Arlington looks to partner with organizations within these industries that save lives, improve effectiveness, and reduce costs. Since inception in 1999, Arlington has invested in over 200 companies and raised over $14 billion in committed capital. The Firm is currently investing out of its $6 billion Fund VII. For more information, visit Arlington’s website at www.arlingtoncap.com and follow Arlington on LinkedIn.

Conference Call Information

The Company will host a conference call on Tuesday, June 9, 2026 at 8:30 a.m. ET to discuss this announcement. To access the call, please dial (888) 346-3959 prior to the scheduled conference call time. Alternatively, the conference call can be accessed online via a live webcast on the Events & Presentations page of the Investors section of the Company’s website at www.novanta.com.

A replay of the audio webcast will be available approximately three hours after the conclusion of the call in the Investor Relations section of the Company’s website at www.novanta.com. The replay will remain available until Tuesday, September 08, 2026.

Safe Harbor and Forward-Looking Information

Certain statements in this news release are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and are based on current expectations and assumptions that are subject to risks and uncertainties. All statements contained in this news release that do not relate to matters of historical fact should be considered forward-looking statements, and are generally identified by words such as “expect,” “intend,” “anticipate,” “estimate,” “believe,” “future,” “target,” “could,” “should,” “may,” “will,” “plan,” “aim,” and other similar expressions. These forward-looking statements include, but are not limited to, the statements of Mr. Glastra and Mr. King in this press release; statements regarding the proposed acquisition of Riverpoint Medical, the expected timing and completion of the transaction, the ability of the parties to satisfy the conditions precedent to consummation of the proposed transaction, including the ability to secure the applicable regulatory approvals on the terms expected, at all or in a timely manner, the anticipated benefits and synergies of the transaction, our ability to successfully integrate Riverpoint Medical, and our ability to implement our plans, forecasts and other expectations with respect to Riverpoint Medical’s business after the completion of the acquisition, expected financial performance and impact, financial position and financial measures and metrics, including expectations regarding accretion, revenue growth, margins, cash flows, leverage ratios and adjusted earnings per share, the expected financing of the transaction statements, our financial outlook for Novanta, Riverpoint Medical and the combined companies, expectations for future growth and prospects, expectations for strategies and business models, and other statements that are not historical facts.

These forward-looking statements are neither promises nor guarantees, but involve risks and uncertainties that may cause future expectations and actions and actual results to differ materially from those contained in the forward-looking statements. Our future expectations and actions and actual results could differ materially from those anticipated in these forward-looking statements as a result of various important factors, including, but not limited to, the following: the risk that the transaction may not be completed on the anticipated timeline or at all; the possibility that any of the anticipated benefits or synergies of the transaction may not be realized; the risk that the business of Riverpoint Medical may not be integrated successfully; risks relating to the financing for the transaction; risks relating to the effect of the announcement of the proposed transaction on the ability of Riverpoint Medical to retain and hire key personnel and maintain relationships with its key business partners and customers, and others with whom it does business, or on its operating results and businesses generally; risks associated with the disruption of our and Riverpoint Medical management's attention from ongoing business operations due to the proposed transaction; the significant costs associated with the proposed transaction; and other important risk factors that could affect the outcome of the events set forth in these statements and that could affect the Company’s operating results and financial condition that are discussed in Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended December 31, 2025, as updated by our subsequent filings with the Securities and Exchange Commission. Such statements are based on the Company’s beliefs and assumptions and on information currently available to the Company. Undue reliance should not be placed on these statements, which are only effective as of the date of this news release. The Company disclaims any obligation to publicly update or revise any such forward-looking statements as a result of developments occurring after the date of this news release except as required by law.

Use of Non-GAAP Financial Measures

The non-GAAP financial measures referenced in this press release include Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Gross Margin, and Adjusted Diluted EPS. A reconciliation of these forward-looking non-GAAP measures to the most directly comparable GAAP financial measures is not provided because of the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliations, including the final purchase price allocation, amortization of acquired intangibles, and other acquisition-related items not available prior to closing. For definitions of these measures and reconciliations of historical non-GAAP results, refer to Novanta's most recent filings with the Securities and Exchange Commission.

More information about Novanta is available on the Company’s website at www.novanta.com. For additional information, please contact Novanta Investor Relations at (781) 266-5137 or [email protected].

More News From Novanta Inc.

Novanta Inc. (NOVT) M&A Call Transcript

On April 15, 2026, Dana Inc DAN shares fell 3.4% to a current price of $35.37. The stock has experienced a 52-week range of $10.85 to $36.95, reflecting significant volatility over the past year.

GF Value™ verdict: Current price is $35.37, while GF Value™ estimates fair value at $13.85, indicating the stock is 155.4% overvalued.GF Score™ of 64/100 suggests that the stock is above average in terms of overall quality and potential for long-term returns.Notable signal: There have been no insider transactions in the last 3 months, indicating a lack of insider confidence or activity. Is DAN Overvalued or Undervalued? The current price of Dana Inc shares at $35.37 is significantly higher than the GF Value™ estimate of $13.85, which suggests that the stock is overvalued by approximately 155.4%. This high degree of overvaluation poses risks for potential investors, as the market price does not appear to reflect the underlying intrinsic value of the company. A substantial margin of safety is crucial for investors looking to enter a position in a stock, and in this case, it is severely lacking.

According to the GF Valuation label, Dana Inc is classified as "Significantly Overvalued." This classification implies that the current market price is not supported by the company's financial fundamentals and growth prospects. While overvalued stocks can still rise in price temporarily, they often carry higher risks of a price correction or increased volatility, making this a critical consideration for potential investors.

How Does DAN's Valuation Compare to Its History? Metric Current Historical P/E (TTM) 52.8x 23.0x Forward P/E 13.2x N/A Dana Inc's current P/E ratio of 52.8x is significantly above its 5-year median P/E of 23.0x, indicating that the stock is trading at a premium compared to its historical valuation. Additionally, the forward P/E of 13.2x suggests a potential decline in earnings expectations. This P/E analysis agrees with the GF Value™ verdict, reinforcing the notion that the stock is currently overvalued.

What Does DAN's GF Score™ Tell Us? Metric Rating GF Score™ 64/100 Financial Strength 4/10 Profitability 6/10 Growth 4/10 Valuation 1/10 Momentum 6/10 The GF Score™ of 64/100 indicates that Dana Inc is above average in terms of overall quality and potential for long-term returns. However, the scores reveal a mixed outlook: while the Profitability and Momentum ratings are relatively stronger at 6/10, the Valuation score is notably low at 1/10, indicating significant overvaluation concerns. Additionally, the Financial Strength and Growth scores of 4/10 suggest that the company may face challenges in maintaining robust financial health and growth in the future.

What Are Insiders Doing with DAN Stock? There have been no insider transactions in Dana Inc stock over the last three months. This lack of insider activity may reflect a cautious stance among executives regarding the company's future prospects or the current market valuation. Typically, insider buying can be a positive signal, indicating confidence in the company's direction, while a lack of activity might raise concerns about management's outlook.

What This Means for Investors Based on the GF Value™ assessment, Dana Inc is currently overvalued. This overvaluation, combined with low margins of safety and weak valuation metrics, suggests that potential investors should exercise caution when considering an investment in this stock.

For the complete analysis, visit the Dana Inc DAN stock page. You can also explore the GF Value™ page for detailed valuation methodology, or use the GuruFocus Stock Screener to find similar opportunities.

Frequently Asked Questions What is DAN's GF Score™?

Dana Inc has a GF Score™ of 64/100, indicating that the stock is above average in terms of quality and potential long-term performance.

Is DAN overvalued or undervalued?

According to the GF Value™ verdict, Dana Inc is significantly overvalued, with the current price of $35.37 being 155.4% above the estimated fair value of $13.85.

What is DAN's P/E ratio?

The current P/E ratio for Dana Inc is 52.8x, which is substantially above its 5-year median P/E of 23.0x, confirming the overvaluation indicated by the GF Value™ analysis.

This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].

Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact , /PRNewswire/ -- Dana Incorporated (NYSE: DAN) announced today that its board of directors has declared a dividend on its common stock.

The board declared a quarterly dividend of $0.12 per share, payable May 29, 2026, to holders of Dana common stock as of May 8.

About Dana Incorporated
Dana Incorporated (NYSE: DAN) is a global leader in the design and manufacture of highly efficient propulsion solutions for the light- and commercial‑vehicle markets. Guided by its vision to be the world's best powertrain company, Dana delivers advanced conventional and clean‑energy technologies that help customers improve the performance, efficiency, and durability of their vehicles. The company supplies leading vehicle manufacturers and related aftermarkets with industry‑defining drive systems, electrodynamic technologies, and thermal and sealing solutions.

Headquartered in Maumee, Ohio, USA, Dana reported sales of $7.5 billion in 2025. With a history dating to 1904, the company employs 27,000 people in 24 countries across six continents. Learn more at dana.com.

SOURCE Dana Incorporated

Also from this source

Dana Incorporated (DAN) Q1 2026 Earnings Call Transcript

On May 19, 2026, Dana Inc DAN shares fell 3.4% today, currently trading at $32.15. Over the past year, the stock has experienced a 104.3% increase, although it has declined 12.9% in the last month, with a 52-week range between $15.31 and $39.56.

GF Value™ verdict: Current price is $32.15 vs GF Value™ of $15.82, indicating the stock is 103.2% overvalued.GF Score™ is 63/100, suggesting the stock is above average in terms of overall quality.Most notable signal: There have been no insider transactions in the last three months. Is DAN Overvalued or Undervalued? Dana Inc DAN is currently trading significantly above its GF Value™, which is estimated at $15.82. With the current price at $32.15, this represents a substantial premium of 103.2%. The GF Valuation label classifies the stock as "Significantly Overvalued," indicating that the current market price does not reflect the intrinsic value of the company based on its financial performance and growth potential. This overvaluation poses a risk for investors, as the stock may be vulnerable to price corrections if market conditions change or if company performance does not meet investor expectations.

GF Value™ is GuruFocus' proprietary measure of intrinsic value, calculated from historical trading multiples, past business growth, and future performance estimates. Investors should be cautious when considering the current price of Dana Inc, as the margin of safety appears to be quite limited.

How Does DAN's Valuation Compare to Its History? Metric Current Historical P/E (TTM) 3.1x 20.8x Forward P/E 12.4x N/A The current P/E (TTM) of 3.1x is significantly below its 5-year median P/E of 20.8x, indicating that the stock is trading well below its historical valuation. However, this analysis aligns with the GF Value™ verdict of overvaluation, suggesting that despite low P/E metrics, the current price does not reflect the company's intrinsic value.

What Does DAN's GF Score™ Tell Us? Metric Rating GF Score™ 63/100 Financial Strength 5/10 Profitability 6/10 Growth 4/10 Valuation 1/10 Momentum 9/10 The GF Score™ of 63/100 indicates that Dana Inc is above average in terms of overall quality. The strongest area is its momentum rank of 9/10, reflecting a positive trend in stock performance. However, the weakest area is the valuation rank, which stands at 1/10, reinforcing the notion that the stock is currently overvalued despite recent strong performance.

What Are Insiders Doing with DAN Stock? There have been no insider transactions in the last three months, suggesting a lack of confidence or interest from the company's executives in buying or selling shares at the current price levels. This inaction might indicate that insiders do not find the stock attractive at its current valuation or are awaiting further developments before making moves.

What This Means for Investors Based on the analysis of the GF Value™, Dana Inc DAN is classified as overvalued. The significant disparity between the current stock price and its intrinsic value suggests that potential risks outweigh the possible rewards at this time.

For the complete analysis, visit the Dana Inc DAN stock page. You can also explore the GF Value™ page for detailed valuation methodology, or use the GuruFocus Stock Screener to find similar opportunities.

Frequently Asked Questions What is DAN's GF Score™?

DAN's GF Score™ is 63/100, indicating that it is above average in overall quality and potential for long-term returns.

Is DAN overvalued or undervalued?

DAN is considered overvalued, with its current price significantly exceeding the GF Value™ of $15.82.

What is DAN's P/E ratio?

DAN's P/E ratio is 3.1x (TTM), which is substantially below its historical 5-year median P/E of 20.8x, further supporting the view of the stock being overvalued.

This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].

SAGUENAY, Quebec, June 02, 2026 (GLOBE NEWSWIRE) -- Arianne Phosphate Inc (the “Company” or “Arianne”) (TSX VENTURE: DAN; OTCQB: DRRSF; FRANKFURT: JE9N), a development-stage phosphate mining company, advancing it's Lac à Paul project in Quebec's Saguenay-Lac-Saint-Jean region, is pleased to announce that it has signed its Joint Venture Framework Agreement with Travertine Technologies Inc. (“Travertine”) which will serve as the template for its final shareholder agreement between the parties. As previously announced (see Press Release dated November 6, 2025), Arianne partnered with Travertine, by way of a Memorandum of Understanding (“MoU”), for the production of purified phosphoric acid (“PPA”) by combining Travertine's proprietary process with Arianne's high-purity phosphate concentrate.

Dana said it has agreed to combine with Eaton's Mobility business in a $5.1 billion deal that would create a more comprehensive supplier serving commercial- and light-vehicle markets.

-

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.

The proposed transaction may contain terms that could limit superior competing offers.

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Dana Incorporated (NYSE: DAN) to Eaton Corporation plc. Upon closing of the Proposed Transaction, Dana shareholders will own approximately 49.9% of the combined company.

Halper Sadeh encourages Dana shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or [email protected] or [email protected].

The investigation concerns whether Dana and its board of directors violated the federal securities laws and/or breached their fiduciary duties by failing to: (1) obtain the best possible price for Dana shareholders; (2) conduct a fair sales process free of any conflicts of interests; and (3) disclose all material information for Dana shareholders to evaluate the transaction.

On behalf of shareholders, Halper Sadeh LLC may seek increased consideration, additional disclosures, or other relief and benefits.

Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

More News From Halper Sadeh LLC

Back to Newsroom

Dana Incorporated (DAN) M&A Call Transcript

-

CHICAGO--(BUSINESS WIRE)--GATX Corporation (NYSE: GATX) will report 2026 first-quarter results prior to market open on May 7, 2026. GATX will hold a conference call later that morning to review the results. Investors can access the call by telephone or via webcast as follows:

Live Teleconference

To participate by phone, please dial in approximately 15 minutes prior to the start time and reference the GATX conference call. To listen via webcast, click the link on GATX’s homepage, www.gatx.com.

Replay Information

COMPANY DESCRIPTION

At GATX Corporation (NYSE: GATX), we empower our customers to propel the world forward. GATX leases transportation assets including railcars, aircraft spare engines and tank containers to customers worldwide. Our mission is to provide innovative, unparalleled service that enables our customers to transport what matters safely and sustainably while championing the well-being of our employees and communities. Headquartered in Chicago, Illinois since its founding in 1898, GATX has paid a quarterly dividend, uninterrupted, since 1919.

AVAILABILITY OF INFORMATION ON GATX'S WEBSITE

Investors and others should note that GATX routinely announces material information to investors and the marketplace using SEC filings, press releases, public conference calls, webcasts and the GATX Investor Relations website. While not all of the information that the Company posts to the GATX Investor Relations website is of a material nature, some information could be deemed to be material. Accordingly, the Company encourages investors, the media and others interested in GATX to review the information that it shares on www.gatx.com under the “Investors” tab.

More News From GATX Corporation

Back to Newsroom

-

CHICAGO--(BUSINESS WIRE)--The board of directors of GATX Corporation (NYSE: GATX) today declared a quarterly dividend of $0.66 per common share, payable June 30, 2026, to shareholders of record on June 15, 2026. This quarterly dividend is unchanged from the prior quarter.

COMPANY DESCRIPTION

At GATX Corporation (NYSE: GATX), we empower our customers to propel the world forward. GATX leases transportation assets including railcars, aircraft spare engines and tank containers to customers worldwide. Our mission is to provide innovative, unparalleled service that enables our customers to transport what matters safely and sustainably while championing the well-being of our employees and communities. Headquartered in Chicago, Illinois since its founding in 1898, GATX has paid a quarterly dividend, uninterrupted, since 1919.

AVAILABILITY OF INFORMATION ON GATX'S WEBSITE

Investors and others should note that GATX routinely announces material information to investors and the marketplace using SEC filings, press releases, public conference calls, webcasts and the GATX Investor Relations website. While not all of the information that the Company posts to the GATX Investor Relations website is of a material nature, some information could be deemed to be material. Accordingly, the Company encourages investors, the media and others interested in GATX to review the information that it shares on www.gatx.com under the “Investors” tab.

More News From GATX Corporation

Back to Newsroom

GATX Corporation (GATX) Q1 2026 Earnings Call Transcript

-

CHICAGO--(BUSINESS WIRE)--Thomas A. Ellman, executive vice president and chief financial officer of GATX Corporation (NYSE: GATX), will present at the Wells Fargo 16th Industrials & Materials Conference on Tuesday, June 9, 2026.

GATX’s presentation will begin at 3 p.m. CT. To listen to a live webcast of the event, please access the appropriate link at www.gatx.com at least 15 minutes prior to the start time. The webcast will be archived for 90 days.

COMPANY DESCRIPTION

At GATX Corporation (NYSE: GATX), we empower our customers to propel the world forward. GATX leases transportation assets including railcars, aircraft spare engines and tank containers to customers worldwide. Our mission is to provide innovative, unparalleled service that enables our customers to transport what matters safely and sustainably while championing the well-being of our employees and communities. Headquartered in Chicago, Illinois, since its founding in 1898, GATX has paid a quarterly dividend, uninterrupted, since 1919.

AVAILABILITY OF INFORMATION ON GATX'S WEBSITE

Investors and others should note that GATX routinely announces material information to investors and the marketplace using SEC filings, press releases, public conference calls, webcasts and the GATX Investor Relations website. While not all of the information that the Company posts to the GATX Investor Relations website is of a material nature, some information could be deemed to be material. Accordingly, the Company encourages investors, the media and others interested in GATX to review the information that it shares on www.gatx.com under the “Investors” tab.

More News From GATX Corporation

Back to Newsroom

-

LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced that it will report financial results for the first quarter 2026 after the market close on Wednesday, April 29, 2026. The Company’s management will host a conference call at 4:30 p.m. ET that same day to discuss the results.

To participate in the conference call via telephone, please click here to pre-register and obtain the dial-in number and passcode.

This conference call will also be webcast and can be accessed from the “Investors” section of CONMED's website at www.conmed.com. The webcast replay of the call will be available at the same site approximately one hour after the end of the call.

About CONMED Corporation

CONMED is a medical technology company that provides devices and equipment for surgical procedures. The Company’s products are used by surgeons and other healthcare professionals in a variety of specialties including orthopedics, general surgery, gynecology, and thoracic surgery. For more information, visit www.conmed.com.

Forward-Looking Statements

This press release and associated conference call may contain forward-looking statements based on certain assumptions and contingencies that involve risks and uncertainties, which could cause actual results, performance, or trends to differ materially from those expressed in the forward-looking statements herein or in previous disclosures. For example, in addition to general industry and economic conditions, factors that could cause actual results to differ materially from those in the forward-looking statements may include, but are not limited to the risk factors discussed in the Company's Annual Report on Form 10-K for the full year ended December 31, 2025 and other risks and uncertainties, which may be detailed from time to time in reports filed by CONMED with the SEC. Any and all forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and relate to the Company’s performance on a going-forward basis. The Company believes that all forward-looking statements made by it have a reasonable basis, but there can be no assurance that management’s expectations, beliefs or projections as expressed in the forward-looking statements will actually occur or prove to be correct.

More News From CONMED Corporation

Back to Newsroom

On April 14, 2026, Conmed Corp CNMD shares rose 3.3% to a current price of $39.73. The stock is trading within a 52-week range of $33.21 to $61.08, reflecting significant volatility over the past year.

GF Value™ verdict: Current price of $39.73 is 49.1% below the GF Value™ estimate of $78.09. GF Score™: 80/100, indicating strong fundamentals. Most notable signal: No insider transactions in the last 3 months. Is CNMD Overvalued or Undervalued? Conmed Corp's current market price of $39.73 is significantly below the GF Value™ estimate of $78.09, suggesting that the stock is undervalued by approximately 49.1%. This substantial margin of safety presents an opportunity for potential investors if the company can execute its business strategy effectively and improve its financial performance. The GF Valuation label indicates that CNMD is significantly undervalued, which may attract attention from value-focused investors looking for opportunities in the medical devices sector.

However, while the undervaluation presents an opportunity, it is important to note the inherent risks involved, including the company's financial strength, as indicated by a score of 5/10. GF Value™ is GuruFocus' proprietary measure of intrinsic value, calculated from historical trading multiples, past business growth, and future performance estimates.

How Does CNMD's Valuation Compare to Its History? Metric Current Historical P/E (TTM) 26.3x 29.9x Forward P/E 9.1x N/A Currently, Conmed Corp's P/E (TTM) of 26.3x is below its 5-year median of 29.9x, indicating that the stock is trading at a lower valuation compared to its historical norm. The forward P/E of 9.1x suggests significant potential for earnings growth, further supporting the notion that the stock is undervalued. This P/E analysis aligns with the GF Value™ verdict, reinforcing the perception of CNMD as an undervalued investment opportunity.

What Does CNMD's GF Score™ Tell Us? Metric Rating GF Score™ 80/100 Financial Strength 5/10 Profitability 7/10 Growth 8/10 Valuation 4/10 Momentum 4/10 The GF Score™ of 80/100 highlights that Conmed Corp has strong fundamentals, particularly in growth (8/10) and profitability (7/10). However, the valuation (4/10) and momentum (4/10) scores indicate potential weaknesses in its current market performance and valuation metrics. This mixed score suggests that while CNMD has solid growth prospects, there are areas requiring improvement, particularly concerning its valuation relative to peers.

What Are Insiders Doing with CNMD Stock? There have been no insider transactions in the last three months for Conmed Corp. This lack of insider trading activity may suggest that company executives are currently not making any significant moves regarding their ownership in CNMD, which could be interpreted as a neutral signal regarding their confidence in the company's near-term performance.

What This Means for Investors Based on the GF Value™ assessment, Conmed Corp CNMD is currently undervalued. The significant gap between the current price and the estimated intrinsic value presents a potential opportunity for investors who are willing to evaluate the company's future performance and risks.

For the complete analysis, visit the Conmed Corp CNMD stock page. You can also explore the GF Value™ page for detailed valuation methodology, or use the GuruFocus Stock Screener to find similar opportunities.

Frequently Asked Questions What is CNMD's GF Score™?

CNMD has a GF Score™ of 80/100, indicating strong fundamentals and potential for long-term returns.

Is CNMD overvalued or undervalued?

CNMD is currently undervalued, with a GF Value™ estimate of $78.09 compared to its current price of $39.73.

What is CNMD's P/E ratio?

CNMD's P/E (TTM) is 26.3x, which is below its 5-year median of 29.9x, indicating a lower valuation compared to its historical performance.

This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].

Conmed (CNMD - Free Report) came out with quarterly earnings of $0.89 per share, beating the Zacks Consensus Estimate of $0.82 per share. This compares to earnings of $0.95 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of +8.98%. A quarter ago, it was expected that this medical technology company would post earnings of $1.32 per share when it actually produced earnings of $1.43, delivering a surprise of +8.33%.

Over the last four quarters, the company has surpassed consensus EPS estimates four times.

Conmed, which belongs to the Zacks Medical - Dental Supplies industry, posted revenues of $317.05 million for the quarter ended March 2026, surpassing the Zacks Consensus Estimate by 2.04%. This compares to year-ago revenues of $321.26 million. The company has topped consensus revenue estimates four times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Conmed shares have lost about 9.4% since the beginning of the year versus the S&P 500's gain of 4.3%.

What's Next for Conmed?While Conmed has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Conmed was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $1.09 on $345.87 million in revenues for the coming quarter and $4.36 on $1.36 billion in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Dental Supplies is currently in the top 23% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

Lifevantage (LFVN - Free Report) , another stock in the same industry, has yet to report results for the quarter ended March 2026. The results are expected to be released on May 6.

This dietary supplements and skin care products company is expected to post quarterly earnings of $0.16 per share in its upcoming report, which represents a year-over-year change of -38.5%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.

Lifevantage's revenues are expected to be $47.82 million, down 18.2% from the year-ago quarter.

CONMED Corporation (CNMD) Q1 2026 Earnings Call Transcript

Investors in CONMED Corporation (CNMD - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the May 15, 2026 $80 Call had some of the highest implied volatility of all equity options today.

What is Implied Volatility?Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It could also mean there is an event coming up soon that may cause a big rally or a huge sell-off. However, implied volatility is only one piece of the puzzle when putting together an options trading strategy.

What do the Analysts Think?Clearly, options traders are pricing in a big move for CONMED shares, but what is the fundamental picture for the company? Currently, CONMED is a Zacks Rank #3 (Hold) in the Medical - Dental Supplies industry that ranks in the Top 26% of our Zacks Industry Rank. Over the last 30 days, the Zacks Consensus Estimate for the current quarter has moved from $1.09 per share to $1.10 in that period.

Given the way analysts feel about CONMED right now, this huge implied volatility could mean there’s a trade developing. Oftentimes, options traders look for options with high levels of implied volatility to sell premium. This is a strategy many seasoned traders use because it captures decay. At expiration, the hope for these traders is that the underlying stock does not move as much as originally expected.